Swiss drugmaker Novartis resumes Ukraine business – Reuters.com

Swiss drugmaker Novartis resumes Ukraine business – Reuters.com

The company’s logo is seen at the new cell and gene therapy factory of Swiss drugmaker Novartis in Stein, Switzerland, November 28, 2019. REUTERS/Arnd Wiegmann/File Photo
ZURICH, June 2 (Reuters) – Novartis (NOVN.S) is resuming business in Ukraine after reviewing how safe it was to operate in the country that Russia invaded in February, the Swiss drugmaker said.
"After studying current safety protocols in the country, and on advice which we will regularly review, we have begun to resume business operations remotely to help the war-torn country restore some basic critical business processes," Novartis said on its website in a post dated June 1.
"The safety and security of our people remains our number one objective, and we will constantly review the situation and our business operations in Ukraine."
Novartis said it condemned the war in Ukraine and has been providing humanitarian support, financial donations and medicine to people there. Russia describes its invasion as a "special military operation" to disarm and "de-Nazify" its neighbour.
Our Standards: The Thomson Reuters Trust Principles.
Chile confirmed on Friday the country’s first case of monkeypox, the health ministry said in a statement.
Reuters, the news and media division of Thomson Reuters, is the world’s largest multimedia news provider, reaching billions of people worldwide every day. Reuters provides business, financial, national and international news to professionals via desktop terminals, the world’s media organizations, industry events and directly to consumers.
Build the strongest argument relying on authoritative content, attorney-editor expertise, and industry defining technology.
The most comprehensive solution to manage all your complex and ever-expanding tax and compliance needs.
The industry leader for online information for tax, accounting and finance professionals.
Access unmatched financial data, news and content in a highly-customised workflow experience on desktop, web and mobile.
Browse an unrivalled portfolio of real-time and historical market data and insights from worldwide sources and experts.
Screen for heightened risk individual and entities globally to help uncover hidden risks in business relationships and human networks.
All quotes delayed a minimum of 15 minutes. See here for a complete list of exchanges and delays.
© 2022 Reuters. All rights reserved

source


Leave a Reply

Your email address will not be published.